Jeff Bartel is chairman and managing director of Hamptons Group, a private investment and strategic advisory firm headquartered in Miami. Gene editing technology, a major biotechnology advance, is ...

Metagenomi announces successful integration of large genes in human cells using a novel, compact CAST system for potential therapeutic applications. Metagenomi, Inc., a precision genetic medicines ...

The inaugural Genetic Agency Technology Conference (GATC) on November 11th, 2025 will convene technical thought leaders, gene therapy developers, patients, their families, and patient advocates across ...

Malaria remains one of the world’s deadliest diseases. Each year malaria infections result in hundreds of thousands of deaths, with the majority of fatalities occurring in children under five. The ...

The alarming fact is that the proposed Bill will allow the release of Gene Edited (Genetically Engineered or Modified) ...

The authors received funding for this work from the now defunded Biological Heritage National Science Challenge. University of Auckland, Waipapa Taumata Rau and University of Otago provide funding as ...

The UWA Tech & Policy Lab receives funding from nationally competitive research grants and philanthropic partners. The present research was supported by GA308883: Effective Ethical Frameworks for the ...

Gene editing, a non-GMO technology, has the potential to revolutionize agriculture by increasing crop yields, making plants more resilient, and meeting the challenges of climate change. Cibus, a ...

Cibus, Inc., a leading agricultural biotechnology firm, announced that Co-Founder and Interim CEO Peter Beetham will present at the AGP Annual Virtual Healthcare Company Showcase on May 21, 2025. He ...

You've probably heard about the gene-editing technology CRISPR. The massive biotech breakthrough, which has emerged in the last decade, has mainly been touted for the ways it will let scientists edit ...

Genetic modification is back on the political agenda in New Zealand. The issue may not be as hotly contentious as it once was ...

A team of researchers report findings from a Phase I/II gene therapy clinical trial for patients with Leber congenital amaurosis, which found that the gene therapy could significantly restore eyesight ...